Induction Therapy versus Initial Surgery in Advanced Thymic Tumors: Perioperative and Oncological Outcome

G. Leuzzi, G. Alessandrini, I. Sperduti, D. Forcella, M. Marino, A. Ceribelli, F. Facciolo

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Background Despite the intense debate concerning management of advanced thymic tumors, no specific oncological strategies have been yet recommended. We report our 13 years' experience to investigate this issue. Methods From 01/2001 to 12/2013, the clinical data of 28 patients treated for Masaoka stages III-IV thymic tumors were retrospectively reviewed. Eleven potentially nonresectable patients (Group A) underwent induction chemotherapy plus surgery, while immediate surgery was performed in 17 patients (Group B). The endpoint was to compare the two groups on (1) surgical resectability; (2) postoperative course; (3) disease-free survival; and (4) overall survival. Results Both groups were comparable in terms of age, gender, clinical stage, clinical tumor size, histology, and adjuvant therapy. Length of surgery was statistically longer in Group A (p = 0.015). Combined surgery and R0 resection was similarly performed in both groups (p = 0.14 and p = 0.99, respectively). The 3-year overall survival was 71.4% for Group A and 93.3% for Group B (p = 0.84). On the other hand, 3-year disease-free survival was 40.5 and 53.7% for Group A and B, respectively (p = 0.67). At multivariate analysis, gender was the strongest predictor for recurrence (hazard ratio = 5.71 [1.22; 26.67], p = 0.03). Conclusion Our results suggest that induction therapy allows obtaining acceptable clinical responses as well as resectability, survival, and recurrence rates. In selected patients with "clinically resectable" stage III-IV cancers, surgery (as first step of a multimodality therapy) could be a feasible treatment option.
Original languageEnglish
Pages (from-to)234-243
Number of pages10
JournalThoracic and Cardiovascular Surgeon
Volume65
Issue number3
DOIs
Publication statusPublished - Apr 1 2017

Fingerprint

Thymus Neoplasms
Disease-Free Survival
Therapeutics
Recurrence
Induction Chemotherapy
Survival
Neoplasms
Histology
Multivariate Analysis
Survival Rate

Cite this

Induction Therapy versus Initial Surgery in Advanced Thymic Tumors: Perioperative and Oncological Outcome. / Leuzzi, G.; Alessandrini, G.; Sperduti, I.; Forcella, D.; Marino, M.; Ceribelli, A.; Facciolo, F.

In: Thoracic and Cardiovascular Surgeon, Vol. 65, No. 3, 01.04.2017, p. 234-243.

Research output: Contribution to journalArticle

@article{f3ec8517b8664a6da181fcf290d20358,
title = "Induction Therapy versus Initial Surgery in Advanced Thymic Tumors: Perioperative and Oncological Outcome",
abstract = "Background Despite the intense debate concerning management of advanced thymic tumors, no specific oncological strategies have been yet recommended. We report our 13 years' experience to investigate this issue. Methods From 01/2001 to 12/2013, the clinical data of 28 patients treated for Masaoka stages III-IV thymic tumors were retrospectively reviewed. Eleven potentially nonresectable patients (Group A) underwent induction chemotherapy plus surgery, while immediate surgery was performed in 17 patients (Group B). The endpoint was to compare the two groups on (1) surgical resectability; (2) postoperative course; (3) disease-free survival; and (4) overall survival. Results Both groups were comparable in terms of age, gender, clinical stage, clinical tumor size, histology, and adjuvant therapy. Length of surgery was statistically longer in Group A (p = 0.015). Combined surgery and R0 resection was similarly performed in both groups (p = 0.14 and p = 0.99, respectively). The 3-year overall survival was 71.4{\%} for Group A and 93.3{\%} for Group B (p = 0.84). On the other hand, 3-year disease-free survival was 40.5 and 53.7{\%} for Group A and B, respectively (p = 0.67). At multivariate analysis, gender was the strongest predictor for recurrence (hazard ratio = 5.71 [1.22; 26.67], p = 0.03). Conclusion Our results suggest that induction therapy allows obtaining acceptable clinical responses as well as resectability, survival, and recurrence rates. In selected patients with {"}clinically resectable{"} stage III-IV cancers, surgery (as first step of a multimodality therapy) could be a feasible treatment option.",
author = "G. Leuzzi and G. Alessandrini and I. Sperduti and D. Forcella and M. Marino and A. Ceribelli and F. Facciolo",
note = "LR: 20170406; CI: Georg Thieme Verlag KG Stuttgart . New York.; JID: 7903387; ppublish",
year = "2017",
month = "4",
day = "1",
doi = "10.1055/s-0035-1564890 [doi]",
language = "English",
volume = "65",
pages = "234--243",
journal = "Thoracic and Cardiovascular Surgeon",
issn = "0171-6425",
publisher = "Georg Thieme Verlag",
number = "3",

}

TY - JOUR

T1 - Induction Therapy versus Initial Surgery in Advanced Thymic Tumors: Perioperative and Oncological Outcome

AU - Leuzzi, G.

AU - Alessandrini, G.

AU - Sperduti, I.

AU - Forcella, D.

AU - Marino, M.

AU - Ceribelli, A.

AU - Facciolo, F.

N1 - LR: 20170406; CI: Georg Thieme Verlag KG Stuttgart . New York.; JID: 7903387; ppublish

PY - 2017/4/1

Y1 - 2017/4/1

N2 - Background Despite the intense debate concerning management of advanced thymic tumors, no specific oncological strategies have been yet recommended. We report our 13 years' experience to investigate this issue. Methods From 01/2001 to 12/2013, the clinical data of 28 patients treated for Masaoka stages III-IV thymic tumors were retrospectively reviewed. Eleven potentially nonresectable patients (Group A) underwent induction chemotherapy plus surgery, while immediate surgery was performed in 17 patients (Group B). The endpoint was to compare the two groups on (1) surgical resectability; (2) postoperative course; (3) disease-free survival; and (4) overall survival. Results Both groups were comparable in terms of age, gender, clinical stage, clinical tumor size, histology, and adjuvant therapy. Length of surgery was statistically longer in Group A (p = 0.015). Combined surgery and R0 resection was similarly performed in both groups (p = 0.14 and p = 0.99, respectively). The 3-year overall survival was 71.4% for Group A and 93.3% for Group B (p = 0.84). On the other hand, 3-year disease-free survival was 40.5 and 53.7% for Group A and B, respectively (p = 0.67). At multivariate analysis, gender was the strongest predictor for recurrence (hazard ratio = 5.71 [1.22; 26.67], p = 0.03). Conclusion Our results suggest that induction therapy allows obtaining acceptable clinical responses as well as resectability, survival, and recurrence rates. In selected patients with "clinically resectable" stage III-IV cancers, surgery (as first step of a multimodality therapy) could be a feasible treatment option.

AB - Background Despite the intense debate concerning management of advanced thymic tumors, no specific oncological strategies have been yet recommended. We report our 13 years' experience to investigate this issue. Methods From 01/2001 to 12/2013, the clinical data of 28 patients treated for Masaoka stages III-IV thymic tumors were retrospectively reviewed. Eleven potentially nonresectable patients (Group A) underwent induction chemotherapy plus surgery, while immediate surgery was performed in 17 patients (Group B). The endpoint was to compare the two groups on (1) surgical resectability; (2) postoperative course; (3) disease-free survival; and (4) overall survival. Results Both groups were comparable in terms of age, gender, clinical stage, clinical tumor size, histology, and adjuvant therapy. Length of surgery was statistically longer in Group A (p = 0.015). Combined surgery and R0 resection was similarly performed in both groups (p = 0.14 and p = 0.99, respectively). The 3-year overall survival was 71.4% for Group A and 93.3% for Group B (p = 0.84). On the other hand, 3-year disease-free survival was 40.5 and 53.7% for Group A and B, respectively (p = 0.67). At multivariate analysis, gender was the strongest predictor for recurrence (hazard ratio = 5.71 [1.22; 26.67], p = 0.03). Conclusion Our results suggest that induction therapy allows obtaining acceptable clinical responses as well as resectability, survival, and recurrence rates. In selected patients with "clinically resectable" stage III-IV cancers, surgery (as first step of a multimodality therapy) could be a feasible treatment option.

U2 - 10.1055/s-0035-1564890 [doi]

DO - 10.1055/s-0035-1564890 [doi]

M3 - Article

VL - 65

SP - 234

EP - 243

JO - Thoracic and Cardiovascular Surgeon

JF - Thoracic and Cardiovascular Surgeon

SN - 0171-6425

IS - 3

ER -